⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Omeros Corporation and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Omeros Corporation
↗Seattle, United States
Omeros Corporation is a commercial-stage biopharmaceutical company focused on discovering and developing first-in-class protein and small-molecule therapeutics. The company targets complement-mediated diseases, cancers, and addictive or compulsive disorders, leveraging its proprietary platforms to address significant unmet medical needs.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Rare Disease/Complement Therapeutics
SIZE & FINANCIALS
Employees:51-200
Founded:1994
Ownership:public
Status:operating
STOCK
Exchange:NASDAQ
Ticker:OMER
Market Cap:$0.76B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, mAb, Protein therapeutics
Active Trials:0
Trial Phases:-
FDA Approvals:1
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Novo Nordisk (acquired global rights to zaltenibart/OMS906), National Institute on Drug Abuse (funds OMS527)
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
Gregory A. Demopulos - Chairman, President and CEO
Peter B. Cancelmo - VP, General Counsel and Secretary
George A. Gaitanaris - Chief Scientific Officer
Scientific Founders:Gregory A. Demopulos
Board Members:Thomas J. Cable, Rajiv Shah, Arnold C. Hanish, Leroy E. Hood
LINKS
Website:omeros.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Omeros Corporation. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.